上腺神经传递通路中的多态性影响了抑郁症患者对抗抑郁药的反应
Taichi Ochi1, Natalya M Vyalova2, Innokentiy S Losenkov2
1Department of PharmacoTherapy, -Epidemiology and -Economics, Groningen Research Institute of Pharmacy, University of Groningen, Antonius Deusinglaan 1, 9713AV, Groningen, the Netherlands.
Neuroscience applied
|July 14, 2025
概括
在SLC6A2基因的遗传变异影响主要抑郁症患者的抗抑郁药反应. 特定的SLC6A2基因型与抑郁症症状得分的显著改善有关,这表明了个性化治疗策略的潜力.
科学领域:
- 神经科学是一个神经科学.
- 药物遗传学 药物遗传学
- 精神病学是一个精神病学.
背景情况:
- 情绪障碍,特别是严重抑郁症 (MDD),是普遍存在的.
- 上腺神经传递途径与抗抑郁药反应有关.
- 遗传变异可能会影响个体对抗抑郁药治疗的反应.
研究的目的:
- 研究上腺素路径中的遗传多态性对MDD患者抗抑郁药反应的影响.
- 为了确定与治疗结果相关的特定单核酸多态 (SNP).
主要方法:
- 招募了163名MDD患者,其中一半以上是以前未接受过治疗的患者.
- 对包括ADRA1A,SLC6A2,ADRβ1,MAOA和COMT在内的基因中的14个SNP进行了基因定型.
- 使用汉密尔顿抑郁症评分表 (HAMD-17) 测量治疗反应,持续时间为四周.
- 多重线性回归分析被用来评估基因型与HAMD-17分数的变化之间的关联,控制共变量.
主要成果:
- 与A/A基因型相比,SLC6A2 rs1532701 G/G基因型在2-4周和整个研究期间与显著改善的抑郁症症状减少 (ΔHAMD-17) 有关.
- 与A/A基因型相比,SLC6A2 rs1532701 A/G基因型在2-4周也显示了 ΔHAMD-17 的改善.
- 总的来说,HAMD-17得分的减少是11.2±4.4 (开始第二周),7.8±5.3 (2-4周) 和19.0±5.3 (整个研究).
结论:
- 上腺素路径中的遗传变异,特别是SLC6A2,与差异性抗抑郁药反应有关.
- 这些发现突显了SLC6A2多态的潜力,作为预测MDD治疗结果的生物标志物.
- 建议进行进一步的研究,包括复制研究和与其他神经递质通路的整合,以完善个性化的抗抑郁药疗法.
相关概念视频
01:23Antidepressant Drugs: MAOIs and Other Agents
372
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
372
01:21Drugs Affecting Neurotransmitter Release or Uptake
1.2K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.2K
01:25Antidepressant Drugs: Overview
777
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
777
01:29Drugs Affecting Neurotransmitter Synthesis
1.6K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.6K
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
588
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
588
01:25Adrenergic Agonists: Indirect-Acting Agents
1.9K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.9K